Moneycontrol
HomeNewsBusinessCompaniesTCS 26th AGM 2021 | IT bellwether lists company's highlights in pandemic-hit FY21. Read full text

TCS 26th AGM 2021 | IT bellwether lists company's highlights in pandemic-hit FY21. Read full text

TCS mentioned, before the shareholders, the company's consolidated revenue growth of 4.6 percent in the COVID-19-hit year; and also reiterated that company's directors have recommended a final dividend of Rs 15 per share.

June 10, 2021 / 17:35 IST
Story continues below Advertisement
TCS is one of the largest employers of women in the world. (File image)

Tata Consultancy Services (TCS), one of the global leaders in IT sector, conducted its 26th annual general meeting (AGM) on June 10 virtually due to the ongoing COVID-19 pandemic. The company presented key highlights of its performance in the pandemic-hit financial year 2020-21.

The Mumbai-headquartered firm presented a brief statistics about the revenue it drew during the fiscal, along with the return to shareholders which has been recommended by the Board of Directors. The Tata Group  subsidiary also pointed out the efforts it has taken for employees amidst the onset of COVID-19 crisis.

Story continues below Advertisement

Here is the full speech by Tata Sons Chairman N Chandrasekaran at the company's 26th AGM -

Good Afternoon Shareholders! I would like to welcome all of you to the 26th Annual General Meeting of the Company.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show